Edition:
United Kingdom

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

78.90USD
23 Feb 2018
Change (% chg)

$0.96 (+1.23%)
Prev Close
$77.94
Open
$78.34
Day's High
$79.62
Day's Low
$77.14
Volume
100,169
Avg. Vol
210,924
52-wk High
$82.06
52-wk Low
$20.39

Select another date:

Tue, Feb 20 2018

BRIEF-Esperion Reports Qtrly Loss Per Share $1.44

* ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Esperion Announces The Appointment Of Jeffrey Berkowitz To Board Of Directors

* ESPERION ANNOUNCES THE APPOINTMENT OF JEFFREY BERKOWITZ TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Esperion Therapeutics Q3 loss per share $1.86‍​

* Esperion provides bempedoic acid franchise development program updates; reports third quarter 2017 financial results

BRIEF-Esperion announces initiation of pivotal late stage study for bempedoic acid

* Esperion announces initiation of pivotal late stage study for the bempedoic acid / ezetimibe combination pill

BRIEF-Esperion Therapeutics - Phase 3 results for bempedoic acid expected in Q2, Q3 2018

* Esperion Therapeutics- bempedoic acid top-line results from studies 1, 3 and 4 are expected in Q2 2018, results from study 2 expected in Q3 2018

Select another date: